Smith Chas P & Associates PA Cpas Decreases Holdings in Merck & Co., Inc. $MRK

Smith Chas P & Associates PA Cpas decreased its stake in Merck & Co., Inc. (NYSE:MRK) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 359,598 shares of the company’s stock after selling 7,925 shares during the period. Merck & Co., Inc. accounts for about 2.2% of Smith Chas P & Associates PA Cpas’ holdings, making the stock its 17th biggest position. Smith Chas P & Associates PA Cpas’ holdings in Merck & Co., Inc. were worth $46,208,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pinnbrook Capital Management LP raised its stake in shares of Merck & Co., Inc. by 95.2% in the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after buying an additional 11,355 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of Merck & Co., Inc. during the 2nd quarter worth $11,470,000. Cibc World Market Inc. increased its holdings in Merck & Co., Inc. by 32.6% in the 4th quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after acquiring an additional 320,143 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Merck & Co., Inc. by 2.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock worth $331,931,000 after acquiring an additional 51,393 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Merck & Co., Inc. by 13.9% in the 4th quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock valued at $193,999,000 after acquiring an additional 224,752 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: HSBC raised its price target for Merck (MRK) from $150 to $172 and maintained a “Buy” rating, implying substantial upside from the recent share price. Benzinga analyst update
• Positive Sentiment: Guggenheim also increased its Merck price target to $170, reinforcing the view that the company’s pipeline, newer medicines and potential cancer-drug combinations can support growth beyond Keytruda. Guggenheim increases Merck price target
• Positive Sentiment: Merck is expanding its development pipeline and commercial portfolio to reduce reliance on Keytruda ahead of its 2028 patent and exclusivity challenges. This provides a longer-term growth narrative, although execution and successful launches remain important. Merck pipeline and new drugs
• Neutral Sentiment: Merck’s stock attracted significant investor attention, but the coverage offers limited new fundamental information. Separately, broader pharmaceutical discussion highlighted manufacturing hurdles for personalized cancer vaccines and risks surrounding confidential industry information. Merck and cancer-vaccine risks
• Negative Sentiment: Investors remain concerned that Merck’s valuation looks demanding relative to its growth rate and to faster-growing peers such as Eli Lilly. Those concerns, combined with the future Keytruda revenue gap, likely contributed to the recent weakness despite higher analyst targets. Merck valuation versus Eli Lilly

Insider Activity

In other news, EVP Chirfi Guindo sold 15,000 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the subject of a number of research reports. Wolfe Research increased their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target on the stock in a research report on Wednesday, August 12th. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. CICC Research initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Finally, BMO Capital Markets raised their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $151.32.

Merck & Co., Inc. Price Performance

Shares of MRK traded down $0.69 during midday trading on Friday, hitting $144.02. 8,677,875 shares of the company traded hands, compared to its average volume of 10,743,099. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $156.92. The firm has a market cap of $355.33 billion, a P/E ratio of 115.22, a PEG ratio of 6.42 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The stock has a 50-day moving average of $136.22 and a 200-day moving average of $124.26.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. During the same period last year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.